Many promising biomarkers for stratifying individuals at risk of developing a chronic disease or subsequent complications have been identified. Research into the potential cost-effectiveness of applying these biomarkers in actual clinical settings has however been lacking. Investors and analysts may
improve their venture decision making should they have indicative estimates of the potential costs and effects associated with a new biomarker technology already at the early stages of its development. To assist in obtaining such estimates, this paper presents a general method for the early health technology assessment of a novel biomarker technology. The setting considered is that of primary prevention programs where initial screening to select high-risk individuals eligible for a subsequent intervention occurs, e.g., prevention of type 2 diabetes. The method is based on quantifying the health outcomes and downstream health-care consumption of all individuals who get reclassified as a result of moving from a screening variant based on traditional risk factors to a screening variant based on traditional risk factors plus a novel biomarker.
As these individuals form well-defined subpopulations, a combination of disease progression modeling and sensitivity analysis can be used to perform an initial assessment of the maximum increase in screening cost for which the use of the new biomarker technology is still likely to be cost-effective.
INTRODUCTION
Much research effort is currently directed at discovering novel biomarkers for identifying individuals at risk of developing a chronic disease (primary prevention) or subsequent complications (tertiary prevention). As these biomarkers provide additional information beyond standard clinical risk factors, applying them in actual clinical settings is expected to result in improved risk stratification. This, in turn, may help to optimize the selection of individuals eligible for a focused intervention, such as behavioral counseling or chemoprevention. Ultimately, this should improve the population's health outcomes at affordable (possibly lower) costs.
After a promising biomarker has been identified and a (prototype) technology has been developed to measure this biomarker in actual clinical settings, its performance needs to be critically evaluated before the new biomarker technology will eventually be adopted in clinical practice. According to Hlatky et al. 1 , such a critical assessment involves six phases, ranging from showing that the levels of the novel biomarker differ between individuals with and without the outcome of interest (proof of concept) to assessing whether using the biomarker improves health outcomes at an affordable cost (costeffectiveness). In this traditional framework, cost-effectiveness analysis is conducted at the end of the product development process. The results are intended to assist health policy makers in deciding whether the new biomarker technology should be routinely adopted in clinical practice. This form of health technology assessment (HTA) is what Pietzsch and Paté-Cornell 2 refer to as classical HTA, to be distinguished from an initial assessment of the likely costs and effects associated with a new medical technology at the early stages of its development process. This so-called early HTA is conducted before the technology has been fully developed and serves to support health technology firms in making appropriate product investment decisions.
Although appropriate quantification of the added predicted value of a novel biomarker over conventional risk factors is a problem of active research and debate [3] [4] [5] [6] [7] [8] [9] , research into the cost-effectiveness of applying such a biomarker in actual clinical settings has so far been limited to two recent case studies in the context of prioritizing patients waiting for coronary artery surgery. 10, 11 A more in-depth discussion on how the cost-effectiveness of using prognostic biomarkers could be established seems therefore desirable. To that end, this paper presents a general method for the early HTA of a novel biomarker technology that is used, in combination with a set of conventional risk factors, as an initial screening test to select high-risk individuals eligible for a subsequent preventive intervention. The use of the method is illustrated in a case study related to the prevention of type 2 diabetes.
Added predictive value and cost-effectiveness of novel biomarker measurement in primary prevention programs
IJzerman and Steuten have recently provided a conceptual model of the medical technology development process. 12 According to their model, this process consists of four main stages: (i) basic research, (ii) translational research, (iii) clinical research, and (iv) market access. Preceding each of these stages is a decision gate where it has to be decided whether to proceed with the next stage, and if so in what direction. In this paper, we assume that the basic research on biological mechanisms is completed and that this has resulted in the identification of several candidate biomarkers. We are therefore at the decision gate preceding the translational research phase, where it has to be decided which of these biomarkers should be selected for further development, if any. The purpose of performing early HTA at this stage of the product development process is to assist health technology firms in making realistic commercial valuations of the conceived new products by providing for each potential new biomarker technology a rough estimate of the maximum additional cost for which its intended clinical application is still likely to be cost-effective. In this section, we will describe how this upper bound on the technology's cost, also known as the commercial headroom available 13 , can be estimated for an improved, biomarker-based screening test.
Consider N individuals who participate in a primary prevention program. The extent to which this reclassification can be considered an improvement can be determined in several ways. 14 Although the NRI and other proposed measures of reclassification are useful for establishing the added predicted ability of a novel biomarker, they do not directly provide insight into which of the risk stratification models would be preferable from a societal perspective. To address this latter aspect, we have to determine whether the increase in added predictive value is sufficient to make changing from to an efficient allocation of scarce health care resources, and this is the domain of health economic analysis. 15 In this type of analysis, it is common practice to assume that all relevant health effects can be aggregated into a single measure of effectiveness. The net monetary benefit (NMB) of an intervention can then be calculated by assuming a threshold value of the decision maker's willingness-to-pay for one unit of health gain. 15, 16 The most common measure of effectiveness is the quality-adjusted life year (QALY), and this is also the one that will be used in the case study. In the remainder of this paper, we will therefore assume that the effectiveness of the two screening variants is evaluated in terms of QALYs. The equations derived in this section are however applicable in all situations where the health consequences are captured in terms of a single measure of effectiveness.
To determine the relative merits of the two screening variants, let and denote the average cost and QALYs associated with screening variant , and let denote the willingness-to-pay (in terms of monetary units) for a QALY. 
Screening variant is then preferred over screening variant if
where and denote the average cost and QALYs associated with applying treatment to the individuals in the th entry of the reclassification table, and where denotes the average screening cost under screening variant .
If we now define and , it follows by substituting (2) and (3) into (1) In Equation (4), this is reflected by the fact that the average beneficial and/ or harmful consequences (in terms of downstream NMB) associated with switching from to , i.e. , are only computed for those individuals who move upwards or downwards in risk classification. For the biomarker-based screening variant to be cost-effective, the overall increase in downstream NMB (i.e., the right-hand side of Equation (4)) needs to be sufficiently large to offset the upfront increase in screening cost, which are incurred by all individuals, irrespective of whether they are reclassified.
PARAMETER ESTIMATION
In this section, we will describe how the parameters at the right-hand side of Equation (4) can be estimated at the decision gate preceding the translational research stage of the medical technology development process. As the amount of clinical data available for estimating these parameters very much depends on whether the biomarker in question has already been measured in a prospective cohort study, we will make a distinction between technologies that aim at providing an alternative way of measuring an existing biomarker and technologies that aim at measuring a completely new biomarker.
General considerations
As the initiation of a preventive intervention is expected to have cost and effect implications on the remainder of a patient's live, the appropriate time horizon for the economic evaluation of such interventions is the patient's lifetime. 15 In such situations, health economic analysts generally rely on disease progression modeling to extrapolate from the event rates and treatment effects observed in clinical trials and observational studies to what would be expected to happen over a lifetime period. 16 The quantitative models used for this purpose typically consist of several discrete health states do not take into account patient heterogeneity are generally referred to as cohort models. 17 For the individuals in the th cell of the reclassification table, the expected cost and QALY consequences of moving from to will depend on three main aspects: (i) the cumulative disease incidence as a function of the time since screening that would be observed in this population in the absence of screening, (ii) the reduction in cumulative disease incidence due to , and (iii) the relative risk of relative to . Our strategy is to derive the health economic consequences that result from these changes in the cumulative disease incidence through disease progression modeling. As the individuals from the different cells of the reclassification 
Prospective data not available
When dealing with a completely new biomarker, nothing will yet be known 
INITIAL ECONOMIC EVALUATION
After the base-case values of all parameters have been specified, the commercial headroom available to the new biomarker technology, denoted by , can be estimated by applying the algorithm depicted in Figure 1 . As the values of most parameters are still uncertain at the early stages of the medical technology development process, the base-case analysis should be followed by an extensive amount of sensitivity analysis to determine the robustness of the obtained results with respect to changes in the parameter values. How the sensitivity analysis can best be conducted depends on the amount of clinical data available. 19 If the added predictive value of the considered biomarker has already been evaluated in a prospective cohort study, the use of probabilistic sensitivity analysis (PSA) seems most appropriate as probability distributions of the parameters of interest can then directly be derived from the data collected within this study. On the other hand, unless expert knowledge has been elicited in a probabilistic way, the use of PSA is generally not feasible when the novel biomarker has not yet been measured in a prospective cohort study. The use of a deterministic approach, such as 1-way sensitivity analysis, would then be more appropriate. It is also possible to perform a multi-way sensitivity analysis by changing two or more parameter values simultaneously. However, the parameter values are still allowed to vary independently from each other as nothing is known about the correlation between these parameters.
ILLUSTRATIVE CASE STUDY
To demonstrate how our proposed method can assist in quantifying the headroom available to an improved, biomarker-based screening test, we applied the method in a case study related to the prevention of type 2 diabetes mellitus (DM2) and its associated micro-and macro-vascular complications.
Clinical context
Lifestyle interventions have previously shown to be a cost-effective strategy to reduce the incidence of DM2 in patients with pre-diabetes. 21 The primary prevention program considered in this case study therefore consists of 
Structure of the disease progression model
To estimate the expected lifetime cost and QALY consequences of applying to subpopulation , we constructed a discrete-time Markov model with three health states (see Figure 2 for a schematic representation): no diabetes, diabetes, and death. The transition probabilities and were assumed to depend on sex and age, whereas the probability of making a transition from the no diabetes to the diabetes state was assumed to depend on the subpopulation and on the treatment that is assigned to these individuals under screening variant . The applied cycle length was one year. 
Value Source
Willingness-to-pay for a QALY 20,000 Reference value
Reclassification table
Size of the study population 4977 [22] Size of subpopulation kl Table 3 [22]
Observed number of DM2 cases in subpopulation kl Table 3 [22]
Fraction of individuals in subpopulation kl
Seven-year incidence of DM2 in subpopulation kl in the absence of screening 
Parameter estimation
A summary of all parameters of interest, their initial values, and the sources used to obtain these values is provided in Table 2 . As the novel biomarker included in had not yet been evaluated in a prospective cohort study, we had to rely on surrogate data to obtain initial values of some of these parameters.
How this was done exactly is briefly described in the subsections below.
Specification of the fractions f kl
Salomaa et al. evaluated whether a combined score of four novel biomarkers (adiponectin, apolipoprotein B, C-reactive protein, and ferritin) could improve the prediction of clinically incident diabetes over and above eleven classical risk factors, including blood glucose. 22 For the purpose of this case study, we assumed that the performance of this biomarker score could serve as a proxy for the performance of the novel biomarker included under . This allowed us to derive initial values of the fractions from the reclassification 
Specification of the transition probabilities of the Markov model
The sex-and age-dependent transition probabilities from the no diabetes to the death state were taken from national life tables. The transition probabilities from the diabetes to the death state were derived from the transition probabilities from the no diabetes to the death state by first converting them into instantaneous death rates and then multiplying these death rates by a relative risk increase (hazard ratio) of , which was obtained from a previously conducted economic evaluation. 24 To estimate , we assumed that the cumulative incidence functions were exponentially distributed, which allowed us to express the underlying instantaneous transition rates as 16 (6) The corresponding one-year transition probabilities can then be expressed as (7) where denotes the hazard ratio comparing individuals receiving the preventive intervention to individuals not receiving a preventive intervention. For this case study, we set , which corresponds to the reduction in DM2 risk observed in the SLIM study. 23 Equations (6) and (7) were subsequently applied to transform the 7-year diabetes incidences as observed in the HEALTH 2000 cohort (Table 3) into initial values of the one-year transition probabilities .
Cost and utility estimates
The cost and utility estimates attached to the Markov model's transient health states were taken from previously conducted economic evaluations. The costs associated with the intensive variant of the lifestyle-intervention program were derived from the SLIM study and were set equal to EUR 800 for the first year and EUR 520 for the second and third year. For the basic variant of the lifestyle-intervention program, these costs were set equal to EUR 320 and EUR 160, respectively.
Specification of the patient characteristics
As we did not have access to the original data used to construct Table 3 , we had to rely on expert judgment to obtain initial values of the mean age and male/female ratio in the different subpopulations . Age is generally considered to be a strong predictor for the development of DM2, and this was taken into account when specifying the base-case values of the mean age in each of the subpopulations . In particular, the mean age in individuals 
Results of the initial economic evaluation

Implications
Based on the results of our initial economic evaluation, we can conclude that if the cost of measuring the novel biomarker is expected to be relatively low, there seems still sufficient room for improving the predictive performance of the existing risk classification models to warrant further research on novel biomarkers that are independently associated with the onset of DM2.
On the other hand, if the unit cost of measuring the novel biomarker is likely to exceed EUR 100, it may be more fruitful to focus the research effort on identifying prognostic biomarkers that have a strong correlation with one of the established risk factors but are less expensive and/or invasive to measure. However, whether such a biomarker would actually be suitable as a substitute for an established risk factor not only depends on the effect size of this new biomarker compared to the established risk factor but also on its whole correlation structure with all the other variables included in the risk stratification model. This should be considered as well when making a go/ no-go decision on the search for such a biomarker.
When performing our analysis, we implicitly assumed that the hypothetical new biomarker will have similar predictive capabilities as the biomarker risk score considered by Salomaa et al. 22 It should therefore be noted that if such a biomarker is expected to have better (worse) capabilities in reclassifying subjects at risk of developing DM2, the cost of measuring the biomarker may be higher (should be lower) than the suggested upper bound of EUR 100.
However, care should be taken not to raise the amount of headroom available too easily as the results of previous studies suggest that the initial expectations of a new biomarker have often been too optimistic, with disappointments in later phases of analyses. 1 Figure 3 : Results of the 1-way sensitivity analysis.
DISCUSSION
Moving from a screening variant based on traditional risk factors to a screening variant based on traditional risk factors plus a novel biomarker results in a reclassification of some of the individuals. To determine the maximum increase in screening cost for which this reclassification is still likely to be cost-effective, we first restructured the decision problem in such a way that part of the parameters of interest could be estimated through disease progression modeling. We then described how these models could be combined with estimated values of the degree of reclassification to obtain initial estimates of the amount of commercial headroom available. Our method was illustrated in a case study related to the prevention of DM2, were a
Markov model with three health states was used to perform an initial economic evaluation of a potential new biomarker technology by using published data on the NRI of related but already clinically validated biomarkers.
A general method for the early HTA of new medical devices has previously been suggested by Pietzsch and Paté-Cornell. 2 Their approach requires an analyst to represent the dependency between the decision variable and the outcome of interest through a sequence of primary and intermediate effect variables, thereby allowing the analyst to obtain concrete realizations of the outcome variable by sampling from a series of conditional probability distributions.
Our method is similar in the sense that we also determine the effect of the decision variable (biomarker-based screening or screening without using the biomarker) on the outcome of interest (the amount of headroom available) by sampling from a series of conditional probability distributions. However, instead of requiring the analyst to provide exact functional forms for each of these probability distributions, we have restructured the decision problem in such a way that some of these distributions can be approximated through disease progression modeling. This makes our method easier to apply in situations were there are no clear functional relationships between the variables of interest, like in our case study related to the prevention of DM2.
A limitation of performing early HTA is that there is generally only a limited amount of clinical data available with which to populate the decision models.
This implies that to be able to compute the amount of headroom available, it is sometimes required to make strong assumptions on some of the unknown parameters, and in this respect our method is no exception. In our case study, this became especially apparent when specifying the values of the cut- is likely to depend on the selected cut-off points, but the clinical data required to estimate this dependency may not be available.
Athough the use of our method provides insight into the amount of headroom available to a novel biomarker, it does not directly provide an answer to the question of whether a medical technology firm should proceed with developing a technology that can measure this biomarker in actual clinical settings. To address this latter aspect, the results of the initial economic evaluation must first be translated into an estimate of the technology's maximum sales price by applying the principle of value-base pricing. 26 This estimate can then be fed into an appropriate product investment evaluation method, such as the one proposed by Girling et al. 27 , to determine whether the expected post-market cash flows are sufficiently large to warrant further investments to transform the current concept into a fully developed end product. When performing such a return-on-investment (ROI) analysis for a specific biomarker technology, one should be aware that the technology can potentially be used for multiple purposes, e.g., not only as a screening test for selecting individuals eligible for a subsequent preventive intervention, but also as a test for monitoring treatment response once the disease has been clinically established. All these potential uses of a new biomarker technology should ideally be taken into account when determining the technology's maximum sales price and estimating the subsequent expected post-market cash flows. However, performing such a comprehensive ROI analysis is not straightforward, and future research on this problem area seems desirable.
To conclude, we presented a method for the early HTA of novel biomarker measurement in primary prevention programs and applied this method in a case study related to the prevention of DM2. Although we have focused on the use of the biomarker as a screening test for identifying individuals at risk of developing a chronic disease, our approach of first identifying the parameters of interest and then restructuring the decision problem in such a way that part of these parameters can be estimated through disease progression modeling seems more generally applicable. Future research effort may therefore be directed at exploring whether it is possible to quantify the clinical value of other potential applications of a new biomarker technology, such as a diagnostic test or a disease monitoring test, in a similar way.
